I
7.16
-0.34 (-4.53%)
| Previous Close | 7.50 |
| Open | 7.48 |
| Volume | 66,466 |
| Avg. Volume (3M) | 70,295 |
| Market Cap | 205,237,360 |
| Price / Sales | 40.44 |
| Price / Book | 87.06 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -273.01% |
| Diluted EPS (TTM) | -3.79 |
| Quarterly Revenue Growth (YOY) | 1,114.80% |
| Total Debt/Equity (MRQ) | 34.04% |
| Current Ratio (MRQ) | 3.74 |
| Operating Cash Flow (TTM) | -22.74 M |
| Levered Free Cash Flow (TTM) | -15.27 M |
| Return on Assets (TTM) | -22.17% |
| Return on Equity (TTM) | -428.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Insight Molecular Diagnostics I | Bullish | - |
AIStockmoo Score
-0.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.63 |
|
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 22.47% |
| % Held by Institutions | 56.26% |
| 52 Weeks Range | ||
| Median | 9.00 (25.70%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 11 Nov 2025 | 9.00 (25.70%) | Buy | 7.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring |
| 07 Jan 2026 | Announcement | iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation |
| 06 Jan 2026 | Announcement | iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch |
| 05 Jan 2026 | Announcement | iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion |
| 10 Nov 2025 | Announcement | IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |